论文部分内容阅读
目的试用白藜芦醇(Res)以提高胰腺癌的疗效。方法分别比较白藜芦醇(Res)、键择(gemcitabine,Gem)和Res+Gem对裸鼠原位胰腺癌模型肿瘤体积、细胞增殖指数和细胞凋亡的影响。结果Res组、Gem组和Res+Gem组肿瘤体积较对照组明显降低,分别为(755.6±155.47)mm3、(328.29±37.92)mm3和(265.6±67.70)mm3,比对照组分别缩小31.2%、70.1%和75.9%。胰腺癌细胞增殖指数对照组为(21.05±2.18)%,Res组为(13.21±2.95)%,Gem组为(10.03±2.86)%,Res+Gem组为(9.02±2.72)%;Res组细胞增殖指数显著低于对照组(P<0.05),Gem+Res组细胞增殖指数显著低于对照组和Res组(P<0.05),但与Gem组无显著差异;胰腺癌细胞凋亡率对照组为(4.7±1.4)%,Res组为(7.5±1.6)%,Gem组为(13.4±1.8)%,Res+Gem为(22.1±3.4)%;Res组细胞凋亡率高于对照组,但无统计学意义(P>0.05),Res+Gem组细胞凋亡率显著高于Res组和Gem组(P<0.05)。结论单用Res治疗胰腺癌的效果比Gem差,但与化疗药物Gem合用能提高胰腺癌的治疗效果。
Objective To investigate the efficacy of resveratrol (Panax) to improve pancreatic cancer. Methods The effects of resveratrol, gemcitabine (Gem) and Res + Gem on the tumor volume, cell proliferation index and apoptosis of pancreatic cancer model in situ were compared. Results The tumor volume of Res group, Gem group and Res + Gem group were significantly lower than that of the control group (755.6 ± 155.47 mm3, (328.29 ± 37.92) mm3 and (265.6 ± 67.70) mm3, respectively, 31.2% 70.1% and 75.9%. The proliferation index of pancreatic cancer cells was (21.05 ± 2.18)% in the control group, (13.21 ± 2.95)% in the Res group, (10.03 ± 2.86)% in the Gem group and (9.02 ± 2.72)% in the Res + Gem group (P <0.05). The proliferation index of Gem + Res group was significantly lower than that of control group and Res group (P <0.05), but not significantly different from that of Gem group. The apoptosis rate of pancreatic cancer cells in control group Was (4.7 ± 1.4)% in Res group, (7.5 ± 1.6)% in Res group, (13.4 ± 1.8)% in Gem group and (22.1 ± 3.4)% in Res + Gem group. The apoptosis rate in Res group was higher than that in control group But no statistical significance (P> 0.05). The apoptosis rate of Res + Gem group was significantly higher than that of Res group and Gem group (P <0.05). Conclusion The effect of single treatment of pancreatic cancer with Res is worse than that of Gem, but combined with chemotherapy drug Gem can improve the therapeutic effect of pancreatic cancer.